Malastad

Proguanil hydrochloride and Atovaquone, the active ingredient in Malastad, is an antimalarial presented as an oral tablet for oral use. It treats and prevents malaria infection, including acute uncomplicated Plasmodium falciparum malaria, in travelers and patients at risk.

GNH USA supplies Malastad as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malastad is an antiprotozoal medication that acts against malaria parasites. It is employed in the following clinical situations:

Malaria prophylaxis: prevents infection in travelers to endemic regions. Acute uncomplicated P. falciparum malaria: treats infection and clears parasites. Mixed-species malaria (non‑falciparum): provides coverage when species identification is uncertain.

Adverse reactions may occur with Malastad use.

Common Side Effects: - Nausea - Abdominal pain - Headache - Dizziness - Rash - Vomiting

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Hepatic dysfunction - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe neutropenia or agranulocytosis - Hemolytic anemia - Severe skin reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS)

Before prescribing Malastad, consider the following precautions: - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown safety; evaluate potential risks to infant. - Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Drug resistance: avoid monotherapy and ensure patient adherence. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Malastad may interact with other medicines. Review the following interactions:

Major Interactions (Avoid): - Rifampin: reduces atovaquone plasma concentrations, compromising efficacy. - Antacids containing aluminum or magnesium: decrease atovaquone absorption. - Cimetidine: may increase atovaquone levels, raising risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Phenytoin: may lower atovaquone concentrations. - Macrolide antibiotics (e.g., erythromycin): may affect metabolism of the combination.